# Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

> **NCT05327686** · PHASE2 · RECRUITING · sponsor: **NRG Oncology** · enrollment: 240 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Unresectable Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Avelumab
- **DRUG:** Axitinib
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **DRUG:** Cabozantinib
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Ipilimumab
- **DRUG:** Lenvatinib
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Pembrolizumab
- **RADIATION:** Stereotactic Ablative Radiotherapy

## Key facts

- **NCT ID:** NCT05327686
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2028-06-15
- **Final completion:** 2028-06-15
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05327686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05327686, "Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05327686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*